ACHV - NIH nods Achieve Life Sciences for evaluation of cytisinicline in cessation of nicotine E-cigarette use

Drazen_/E+ via Getty Images Achieve Life Sciences ([[ACHV]]) awarded a grant from the National Institute on Drug Abuse of the National Institutes of Health (or NIH) to evaluate the use of cytisinicline as a treatment for cessation of nicotine e-cigarette use. The initial grant to commence on August 1, 2021 and will be utilized to complete critical regulatory and clinical operational activities. Achieve expects to receive the next stage of the grant award that will enable initiation of the Phase 2 ORCA-V1 clinical study evaluating cytisinicline in approximately 150 adult nicotine e-cigarette users in the US. Use of e-cigarettes continues to be widespread, with most recent reports from the Centers for Disease Control and Prevention indicating that there were nearly 11M adult users in the US alone in 2019. More insight on the stock in SA contributor article, 'OncoGenex Pharmaceuticals: In The Midst Of A Possible Turnaround'

For further details see:

NIH nods Achieve Life Sciences for evaluation of cytisinicline in cessation of nicotine E-cigarette use